Treatment
Aflibercept clinical trials
We’re tracking 34 recruiting studies that include Aflibercept, each written for real people, not researchers, below.
Recruiting studies
- NCT07734844RecruitingPhase 3
New vs existing treatment for diabetic macular edema
This study compares a new medication, tabirafusp tedromer, to an existing treatment, aflibercept, for people with diabetic macular edema (swelling in the back of the eye from diabetes). It may help if your DME hasn't improved or you're looking for a new option.
Glendale, CaliforniaAges 18 years+ - NCT07614776RecruitingPhase 3
New Eye Injection Treatment for Age-Related Macular Degeneration
This study tests whether a new eye injection called ABP 938 works as well as or better than the current standard treatment (Eylea) for wet age-related macular degeneration—a condition that causes vision loss in the center of your sight. You would receive injections into your eye every month for a year.
Fullerton, CaliforniaAges 50 years+ - NCT07640997Recruiting
Real-world study of aflibercept for age-related macular degeneration
This study follows patients receiving aflibercept 8 mg injections in the eye to treat wet age-related macular degeneration (nAMD), a condition that blurs central vision. The goal is to understand how well this treatment works and its safety in routine medical practice.
Beijing, Beijing MunicipalityAges 50 years+ - NCT07489131RecruitingPhase 3
Comparing a new macular edema treatment to Eylea HD
This study tests whether a new drug (AVT29) is as safe and effective as the standard treatment Eylea HD for people with diabetic macular edema (DME) — a condition where fluid builds up in the back of the eye due to diabetes. If you have vision loss from DME and haven't had anti-VEGF injections before, you may be able to join.
BudapestAges 18 years+ - NCT07449936RecruitingPhase 3
Comparing a new long-lasting injection to standard one for DME
This phase 3 trial tests a new long-acting injection (EYP-1901) against a standard one (aflibercept) for people with diabetic macular edema. Both treatments are given as eye injections, and the goal is to see if the new drug works as well and may require fewer injections.
Bakersfield, CaliforniaAges 18 years+ - NCT07449923RecruitingPhase 3
Comparing a new injection to standard treatment for diabetic macular edema
This trial compares a new treatment (EYP-1901, given as an injection) to a standard injection (aflibercept) for people with diabetic macular edema. It aims to see which works better at reducing swelling and improving vision.
Gilbert, ArizonaAges 18 years+ - NCT05885503RecruitingPhase 3
Testing an eye injection for diabetic macular swelling
This Phase 3 study compares a new eye injection (RC28-E) with the standard treatment (aflibercept) for diabetic macular edema, which is swelling in the central retina that affects vision. It aims to see whether the new treatment works as well and is safe.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06850571RecruitingPhase 4
Comparing two eye injections for diabetic macular edema
This trial compares two standard anti-VEGF injections (aflibercept and bevacizumab) for people with diabetic macular edema who have not recently had this treatment. The goal is to see which drug works better over three monthly doses to improve vision and reduce retinal swelling.
BaghdadAges 40 years+ - NCT07338097Enrolling by invitation
Comparing two eye injections for diabetic macular edema
This study tests whether one eye injection (aflibercept) works better than another (bevacizumab) for people with diabetic macular edema. Both are already used for this condition, and the goal is to see which provides better vision improvement.
Multan, Punjab ProvinceAges 30–60 - NCT07423429Recruiting
Switching to Aflibercept 8 mg for wet AMD
This trial tests if switching to a higher dose of aflibercept (Eylea) can help people with wet age-related macular degeneration (AMD) who need frequent eye injections. If you've been on other anti-VEGF injections for over a year and still need them more often than every 12 weeks, this study might offer a new option.
Nantes, NantesAges 18 years+ - NCT04519619Recruiting
Safety study of aflibercept eye injections in Japanese glaucoma patients
This trial checks how safe aflibercept (eye injection) is for Japanese people with neovascular glaucoma. You may be able to join if you already received aflibercept treatment under the approved Japanese instructions and have the correct diagnosis.
Multiple LocationsAges Any age - NCT06121180RecruitingPhase 2
Cemiplimab plus ziv-aflibercept for metastatic uveal melanoma
This trial tests two drugs, cemiplimab and ziv-aflibercept, together for people whose uveal melanoma has spread. It may be an option if previous treatments have stopped working or you haven't had treatment yet.
Los Angeles, CaliforniaAges 18 years+ - NCT06315556Recruiting
Study of Eylea for preterm babies with retinopathy of prematurity in the UK
This study collects information on how the medicine Eylea is given to preterm babies with retinopathy of prematurity (an eye problem in premature infants) using a special dosing device. The goal is to see how the treatment works in everyday hospital care.
Multiple LocationsAges Up to 1 year - NCT06662994RecruitingPhase 4
High dose aflibercept for diabetic macular edema after vitrectomy
This trial tests a high-dose version of the drug aflibercept (given as an eye injection) for people with diabetic macular edema who have previously had a vitrectomy surgery. The goal is to see if this higher dose can help reduce swelling and improve vision.
Fullerton, CaliforniaAges 21 years+ - NCT07235527Recruiting
Aflibercept biosimilar for wet age-related macular degeneration
This study tests a biosimilar version of aflibercept (a drug that blocks abnormal blood vessel growth) in people with wet age-related macular degeneration. It aims to see how well the treatment works in real life.
Istanbul, şişliAges 45–90 - NCT07389980RecruitingPhase 3
Personalized high-dose aflibercept for a type of wet AMD
This trial tests a higher dose of aflibercept (a drug that blocks abnormal blood vessel growth) for people with a specific form of wet age-related macular degeneration called polypoidal choroidal vasculopathy. The goal is to see if a personalized treatment plan with this stronger dose is safe and effective for those who have not been treated before.
DaeguAges 19 years+ - NCT02669953Recruiting
Aflibercept injections for persistent wet macular degeneration
This trial studies whether aflibercept injections can help when “wet” age-related macular degeneration is recurring or not fully going away. It focuses on adults who have already had ranibizumab and still have measurable vision in the study eye.
ViennaAges 50 years+ - NCT07434713Recruiting
Testing early response to Eylea 8mg for wet AMD
This study looks at how quickly fluid in the retina clears after starting treatment with a higher dose of Eylea (aflibercept 8mg) for wet age-related macular degeneration (AMD). It aims to understand if early fluid changes can predict long-term outcomes.
BernAges 50 years+ - NCT07776522RecruitingPhase 2
Gene therapy for wet age-related macular degeneration
This trial tests a one-time gene therapy injection under the retina for people with wet age-related macular degeneration (AMD), which causes blurry vision from abnormal blood vessels. It aims to reduce the need for frequent eye injections by delivering a treatment that may help the eye produce its own medicine.
Beijing, Beijing MunicipalityAges 50–85 - NCT05197270RecruitingPhase 1/Phase 2
Gene therapy for wet age-related macular degeneration
This study tests a new gene therapy called 4D-150 for people with wet age-related macular degeneration (AMD). It aims to reduce the need for frequent anti-VEGF injections by delivering a long-lasting treatment into the eye.
Phoenix, ArizonaAges 50 years+ - NCT07317934RecruitingPhase 3
Gene therapy for wet age-related macular degeneration
This study tests a one-time gene therapy called LX102 for wet age-related macular degeneration (AMD). It may reduce the need for frequent eye injections and help preserve vision.
Hefei, AnhuiAges 50–80 - NCT07440225RecruitingPhase 2/Phase 3
Testing a new drug for wet macular degeneration
This trial tests a new medicine called EYE201/MK-8748 for people who have wet age-related macular degeneration (a condition where abnormal blood vessels grow under the retina). It's for those who haven't had treatment before and were diagnosed recently.
Scottsdale, ArizonaAges 50 years+ - NCT07496567RecruitingPhase 2/Phase 3
Study of EYE201 for wet age-related macular degeneration
This trial tests a new medicine, EYE201, for people with wet age-related macular degeneration (AMD) that has not been treated before. The study will see if this drug can help improve vision and slow down vision loss.
Gilbert, ArizonaAges 50 years+ - NCT06893965Recruiting
Eye pressure check after Eylea 8mg injection
This trial measures eye pressure right after an injection of a higher-dose Eylea (aflibercept 8mg) to see how it affects the eye. It may help people who need frequent anti-VEGF shots for conditions like wet AMD or diabetic eye disease.
Toulon, VarAges 18 years+
What Aflibercept is being studied for
Conditions with recruiting Aflibercept studies.
- Diabetic Macular Edema
- Age-Related Macular Degeneration
- Exudative Age-Related Macular Degeneration
- Neovascular Age-Related Macular Degeneration (nAMD)
- Macular Degeneration
- Choroidal Neovascularization
- Wet Macular Degeneration
- Intravitreal Injections
- Neovascular (Wet) Age-Related Macular Degeneration
- Metastatic Uveal Melanoma
Common questions
- Are there clinical trials studying Aflibercept?
- Yes. Clin2 currently lists 34 recruiting studies that include Aflibercept, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Aflibercept trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Aflibercept an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Aflibercept or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.